Company intelligence / Profile preview

Abioniv

Ownership: Private
Development stage: Other

Overview

Abioniv provides expertise in the science of inactivating microorganisms for purposes such as disinfection and bioengineering. Their offerings seem focused on leveraging microbial processes or controlling them for health-related applications. There is no public information about clinical trials or drug development results.

Therapeutic areas: Infectious DiseasesOther
Modalities: BiologicMicrobial therapyDisinfection technologies
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Abioniv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abioniv.

Explore the full profile